A Drug Got Rejected Over a Factory Problem. The Fix Wasn't Fixing the Factory.

In September 2025, Scholar Rock received a Complete Response Letter from FDA for apitegromab, its lead drug candidate for spinal muscular atrophy. The rejection had nothing to do with the drug's clinical data. It came from observations identified during a routine FDA inspection of a third-party fill-finish facility — Catalent Indiana, part of Novo Nordisk — that had nothing to do with whether apitegromab actually worked. A drug with genuinely compelling clinical results was stopped cold by a manufacturing-site inspection finding at a facility the drug's own sponsor didn't own or directly control.

On September 11, 2026 — nineteen days ahead of its September 30 PDUFA deadline — FDA approved ISEMBYLD (apitegromab-mstn) as the first and only muscle-targeted treatment for SMA. The clinical story is genuinely notable: after decades of industry-wide failed attempts to translate myostatin biology into an approved therapy, Scholar Rock succeeded. But the more instructive story, for anyone running regulatory strategy in an industry that increasingly relies on third-party manufacturing, is what happened between the rejection and the approval — because Scholar Rock didn't fix Catalent Indiana. It stopped depending on it.

What actually happened between the CRL and the approval

Rather than waiting on Catalent Indiana to resolve whatever the FDA inspection had flagged, Scholar Rock pursued a fundamentally different strategy: qualify a second, independent fill-finish facility, and resubmit the BLA referencing both sites as parallel, independent paths to approval. That's a meaningfully different response than the conventional playbook, which typically treats a facility-driven CRL as a problem to be fixed at the source — remediate the cited facility, document the corrective actions, and resubmit once the same site passes reinspection. Scholar Rock's March 2026 resubmission included two fill-finish facilities specifically so that a problem at either one wouldn't single-handedly block the entire approval again.

The company went further than simple redundancy as the process played out. Rather than continuing to carry Catalent Indiana as a second, contingent pathway once the second facility's qualification was progressing well, Scholar Rock and FDA agreed in August 2026 to remove Catalent Indiana from the BLA entirely and let the review proceed solely on the second facility. That's a striking sequence: a company voluntarily dropping a facility from its own approval pathway, mid-review, rather than defending or continuing to wait on it — a decision that only makes sense if the redundancy strategy had already de-risked the outcome enough that the original facility's inclusion was providing more residual risk than optionality.

Why this is a better case study than a typical facility remediation story

Facility-related CRLs are not rare, and the standard narrative around them is fairly well worn: a manufacturing site fails an inspection, the sponsor works with the site to remediate, FDA reinspects, and the application eventually clears once the same facility passes. That story is fundamentally about fixing a single point of failure. Scholar Rock's story is about not having a single point of failure in the first place — or more precisely, building one in after the fact, once a single point of failure had already cost the company a rejection and roughly a year of delay.

The distinction matters because it reflects two different theories of where manufacturing risk actually lives. The remediation-focused approach treats a facility's compliance status as the risk to manage — get this specific site compliant, and the problem is solved. Scholar Rock's approach, at least as it played out here, treats reliance on any single third-party facility as the risk to manage, independent of that facility's current compliance status — because a facility that passes today's inspection can still fail tomorrow's, and a sponsor with no alternative pathway is fully exposed to that possibility regardless of how well the facility performs on average. Given that Scholar Rock's original CRL stemmed from an inspection finding at a facility operated by Novo Nordisk — a large, sophisticated, well-resourced manufacturer, not a marginal contract player — the lesson isn't "pick better contract manufacturers." Even large, capable manufacturing partners can generate an inspection finding that stops an otherwise-approvable drug in its tracks, which is precisely why redundancy, not vendor selection alone, is the more durable mitigation.

The regulatory engagement pattern worth noting too

The path from CRL to approval also shows a specific, replicable pattern of FDA engagement that's worth extracting on its own. Scholar Rock didn't simply resubmit and hope; it secured a Type C meeting with FDA in March 2026 specifically to align on what a resubmission with two facilities would need to include, and it used that same engagement channel again in August to align on removing Catalent Indiana once the second facility's position had strengthened. Each major strategic pivot — adding the second facility, later dropping the first — was preceded by direct FDA engagement to confirm the agency's alignment before committing to the change, rather than making the call unilaterally and hoping FDA's eventual review agreed with the sponsor's read of the situation.

That's a meaningfully different posture than treating a CRL as primarily a documentation exercise to satisfy on the next submission. It treats the path back to approval as an active, iterative negotiation about acceptable evidence and acceptable risk, conducted transparently with the reviewing division at each significant decision point, rather than a single remediation plan executed in isolation and then submitted for a verdict. Given that Scholar Rock ultimately beat its own PDUFA deadline by nineteen days, that engagement pattern appears to have paid off in review efficiency, not just in avoiding a second rejection.

What this means for other sponsors relying on third-party manufacturing

The single-facility dependency problem Scholar Rock ran into isn't unique to SMA drugs or to myostatin biology — it's structural to how a large share of the industry manufactures biologics and complex injectables, where fill-finish capacity is concentrated among a relatively small number of specialized contract manufacturers, and where qualifying an additional, fully independent site is expensive and slow enough that most sponsors don't do it until something forces the question. Scholar Rock's experience suggests that "something" doesn't need to be a company's own facility failing — it can be any facility in the chain, including one operated by a manufacturing partner with a strong general track record, failing an inspection for reasons that have nothing to do with the sponsor's own quality practices.

For sponsors currently relying on a single fill-finish or manufacturing site for a pipeline asset approaching a BLA or NDA submission, the practical question worth asking now, rather than after a CRL arrives, is whether a second qualified site is a genuine near-term option — not because the current site is expected to fail, but because the cost of discovering it's the only path to approval is a Complete Response Letter and a year of delay, as Scholar Rock's own timeline shows. And for sponsors already holding a CRL tied to a facility-specific finding, Scholar Rock's sequence — engage FDA directly and early on what a redundant pathway would need to look like, rather than defaulting to remediation of the cited site as the only route back — is a genuinely different playbook worth considering, particularly when the cited facility is a large, capable operator where remediation timelines are themselves uncertain.

Sources: Scholar Rock Holding Corporation SEC filings (Forms 8-K and 10-Q, 2026); Scholar Rock press releases, March 31, August 7, and September 11, 2026; U.S. Food and Drug Administration approval records for ISEMBYLD (apitegromab-mstn).